As healthcare professionals, we often encounter gastrointestinal bleeding (GIB) in our practice. The management of this condition requires a comprehensive understanding of its etiology, diagnostic modalities, and therapeutic options.
GIB can be classified into upper and lower based on its origin. Peptic ulcer disease, esophageal varices, and gastritis are common causes of upper GIB, while diverticulosis, colorectal cancer, and angiodysplasia often lead to lower GIB. Identifying the source is crucial for effective treatment.
Endoscopy remains the gold standard for diagnosing GIB. Upper endoscopy is usually performed first, except in cases with obvious signs of lower bleeding. Colonoscopy and capsule endoscopy are also valuable tools. Imaging studies and angiography can be used when endoscopic methods are inconclusive or contraindicated.
Initial management includes hemodynamic stabilization and risk stratification. Endoscopic therapy is the first-line treatment for most causes of GIB. Pharmacological therapy, such as proton pump inhibitors for peptic ulcers and vasoactive drugs for variceal bleeding, is also essential. Surgery or interventional radiology may be required for refractory or recurrent bleeding.
Preventive measures, such as the use of nonsteroidal anti-inflammatory drugs and anticoagulants, should be reviewed. Follow-up endoscopy is often recommended to ensure healing and prevent rebleeding. Long-term management strategies should be personalized based on the patient's condition and risk factors.
Managing GIB requires a comprehensive approach, from understanding its etiology to implementing appropriate treatment and preventive measures. As healthcare professionals, we must stay updated on the latest evidence to provide the best care for our patients.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation